In one patient with RR CD33+ AML, CD33 CAR-T cell infusion led to rapid degradation of blasts in the BM within 2 weeks of infusion; however, the disease relapsed after 9 weeks as CD33+ blasts gradually increased. This evidence concerns the gene CD33 and acute myeloid leukemia.